Piper Sandler keeps an Overweight rating on ALX Oncology with an $8 price target ahead of the Phase 2 ASPEN-06 data for evorpacept in second-line HER2+ gastric/gastroesophageal junction cancer. The firm likes the stock’s risk/reward heading into the event and remains a buyer of the name. Piper says it is “hard to see sentiment much worse” into the data, which it believes creates a “compelling” risk/reward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology Realigns Executive Leadership Team
- ALX Oncology files to sell 18.45M shares of common stock for holders
- ALX Oncology Announces September Investor Conference Participation
- ALX Oncology price target lowered to $8 from $48 at Piper Sandler
- ALX Oncology price target lowered to $18 from $22 at Cantor Fitzgerald